Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
35 /100
COMPONENT-LIMITED
Score updated Aug 28, 2026

TCRX — TScan Therapeutics, Inc. Dilution Risk Tracker

Track TCRX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track TCRX — Get alerts when the score changes →

As of August 28, 2026, TScan Therapeutics, Inc. (TCRX) has a DilutionWatch DilutionScore of 35/100, rated MEDIUM dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. TScan Therapeutics, Inc. has a market capitalization of $70.58M, 23.98M shares outstanding, 62 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
42
💰 Cash Runway
40
📊Float Risk
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

Watch
Minor dilution signals detected
model est. 15%
🔄 Reverse Split model est. 30%
• 50-day avg $1.11 approaching $1 threshold
🔔 Track TCRX — Get forecast alerts →

Market Data

Market Cap$70.58M
Shares Outstanding23.98M
FloatN/A
Cash$115.10M
Debt$32.78M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 16.5% shares (2026Q1 vs prior)
62 institutional holders · 36.15M shares
#1 Lynx1 Capital Management LP 8.02M shares
#2 BVF INC/IL 5.56M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 4.31M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest1.56M
Days to Cover2.8
% of FloatN/A
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2024-12-31
4 INSIDER TRANSACTION 2026-01-22
4 INSIDER TRANSACTION 2026-01-22
4 INSIDER TRANSACTION 2026-01-22
4 INSIDER TRANSACTION 2026-01-22
Full SEC filing analysis available with free account

Recent News

No recent news

Factual TCRX Dilution Snapshot

TScan Therapeutics, Inc. (TCRX) has a DilutionScore of 35/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track TCRX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking TCRX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for TCRX
TCRX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.